Rheumatoid Arthritis Completed Phase 2 / 3 Trials for Abatacept (DB01281)

Also known as: Rheumatoid Arthritis(RA) / Rheumatoid Arthritis, NOS / Rheumatoid Arthritis RA / Rhematoid Arthritis / Rheumatic Arthritis / Rheumatoid Arthritis (RA) / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Arthritis, Rheumatoid (RA) / Rheumatoid Arthritis(RA) / RA / Systemic rheumatoid arthritis / Rheumatoid arthritis (disorder) / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Rheumatoid arthritis NOS / Rheumatoid arthritis NOS (disorder)

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01333878Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural DamageTreatment
NCT01001832Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsTreatment